Genome Editing Market Size to Worth USD 38.19 Billion by 2033

Prathamesh

8 months ago

The global genome editing market size is expected to increase USD 38.19 billion by 2033 from USD 7.98 billion in 2023 with a CAGR of 16.95% between 2024 and 2033.

Key Points

The North America genome editing market size reached USD 3.83 billion in 2023 and is expected to attain around USD 18.52 billion by 2033, poised to grow at a CAGR of 17.06% between 2024 and 2033.
North America led the market with the largest revenue share of 48% in 2023.
Asia Pacific is expected to expand at a solid CAGR of 18.75% during the forecast period.
By technology, the CRISPR/Cas9 segment has contributed more than 45% of revenue share in 2023.
By technology, the ZFN segment is projected to grow at a notable CAGR of 16.57% during the forecast period.
By delivery methods, the ex-vivo segment has held a major revenue share of 52% in 2023.
By delivery methods, the in-vivo segment is expected to grow with the highest CAGR of 19.24% during the forecast period.
By application, the genetic engineering segment dominated the market in 2023.
By application, the clinical applications segment is estimated to expand at the solid CAGR of 13.20% during the forecast period.
By mode, the contract segment led the market in 2023.
By mode, the in-house segment is expected to be the fastest-growing segment in the market.
By end-use, the biotechnology and pharmaceutical companies segment has held a biggest revenue share of 51% in 2023.
By end-use, the academic and research institutions segment is estimated to at a remarkable CAGR of 19.23% during the forecast period.

The Genome Editing Market is experiencing significant growth driven by advancements in biotechnology and genetic engineering. This market encompasses technologies that enable precise modification of DNA within living organisms, offering potential applications in agriculture, healthcare, and biotechnology research. Key technologies include CRISPR/Cas9, TALENs, and zinc finger nucleases, each offering unique advantages in terms of precision, efficiency, and applicability across various organisms. In healthcare, genome editing holds promise for treating genetic disorders, while in agriculture, it enables the development of crops with enhanced traits such as resistance to pests or improved nutritional profiles. The market is characterized by robust research activities, strategic partnerships, and increasing investments aimed at harnessing the full potential of genome editing across diverse fields.

Get a Sample: https://www.precedenceresearch.com/sample/4563

Genome Editing Market Scope

Report Coverage	Details
Market Size by 2033	USD 38.19 Billion
Market Size in 2023	USD 7.98 Billion
Market Size in 2024	USD 9.33 Billion
Market Growth Rate from 2024 to 2033	CAGR of 16.95%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	Technology, Delivery Method, Application, Mode, End-use, and Regions
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Genome Editing Market Dynamics

Drivers

The Genome Editing Market is driven by advancements in CRISPR/Cas9 technology, which has revolutionized the precision and efficiency of genetic manipulation. This technology allows for targeted modifications in DNA sequences with unprecedented accuracy, fostering rapid progress in gene therapy, drug development, and agricultural biotechnology. Moreover, increasing research activities in genomics and personalized medicine have bolstered market growth, as scientists and healthcare providers seek innovative solutions for treating genetic disorders and developing customized therapies.

Challenges

Despite its promising potential, the Genome Editing Market faces several challenges. Off-target effects remain a critical concern, where unintended modifications in the genome may occur, posing risks to patient safety and regulatory approval. Ethical considerations surrounding germline editing and genetic manipulation in humans also present significant regulatory and societal challenges. Additionally, the complexity and variability of genetic diseases necessitate extensive research and validation of editing techniques, adding to development costs and timelines.

Opportunities

The Genome Editing Market offers substantial opportunities across various sectors. In healthcare, the ability to correct genetic mutations holds promise for treating previously incurable diseases, driving demand for therapeutics targeting rare genetic disorders and cancers. Agriculture stands to benefit from genome-edited crops with enhanced yield, resistance to diseases, and improved nutritional profiles, addressing global food security challenges. Furthermore, advancements in delivery methods for genome-editing tools, such as nanoparticles and viral vectors, open new avenues for precise and efficient gene therapy applications.’

Genome Editing Market Segmentation

Technology

The Genome Editing Market is witnessing significant advancements driven by various technologies such as CRISPR/Cas9, TALENs, and zinc finger nucleases (ZFNs). CRISPR/Cas9, in particular, has emerged as a leading technology due to its simplicity, precision, and versatility in editing genes. It enables researchers to target specific DNA sequences with unprecedented accuracy, revolutionizing genetic research and therapeutic applications.

Delivery Method

Delivery methods for genome editing tools play a crucial role in their efficacy and safety. Viral vectors, including adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are commonly used for delivering CRISPR/Cas9 and other editing components into target cells. Non-viral methods such as lipid nanoparticles and electroporation are also being explored for their potential to deliver editing tools efficiently without the drawbacks associated with viral vectors.

Application

Genome editing technologies have diverse applications across various sectors, including biotechnology, pharmaceuticals, agriculture, and research. In biotechnology and pharmaceutical industries, genome editing is utilized for developing novel therapies for genetic disorders, cancer treatment, and personalized medicine. In agriculture, it holds promise for enhancing crop resilience, improving nutritional content, and developing disease-resistant varieties.

Mode

The mode of genome editing refers to its use in therapeutic and research settings. In therapeutic applications, genome editing is advancing towards clinical trials and potential commercialization for treating genetic diseases and disorders. Research applications span basic research in genetics and molecular biology, enabling scientists to elucidate gene functions, develop disease models, and study complex biological pathways.

End-use

The end-use of genome editing technologies varies across different sectors and applications. Biotechnology and pharmaceutical companies are leading adopters, leveraging genome editing for drug discovery, development of gene therapies, and production of biopharmaceuticals. Research institutions and universities also heavily utilize genome editing tools for basic research and academic studies, contributing to advancements in understanding genetic mechanisms and disease pathways.

Regional Insights

The genome editing market is experiencing significant growth across various regions globally. North America leads the market due to substantial investments in biotechnology and pharmaceutical research, coupled with supportive government initiatives. Europe follows closely, driven by advancements in gene therapy and increasing R&D activities. Asia-Pacific is emerging as a lucrative market, propelled by rising healthcare expenditure and expanding biotechnology sector in countries like China and India. Latin America and Middle East & Africa are also witnessing growth, aided by increasing awareness and adoption of advanced medical technologies. Overall, the genome editing market shows promise across diverse geographic regions, supported by continuous innovation and expanding applications in healthcare and agriculture.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/4563

Genome Editing Market Companies

Merck KGaA.
Cibus Inc.
Recombinetics
Sangamo Therapeutics
Cellectis S.A.
AstraZeneca
Takara Bio Inc.
Horizon Discovery Ltd. (Revvity, Inc.)
Editas Medicine
Precision BioSciences
CRISPR Therapeutics
Intellia Therapeutics, Inc.
Caribou Biosciences, Inc
Danaher Corporation
Transposagen Biopharmaceuticals, Inc.
Genscript Biotech Corp
New England Biolabs
OriGene Technologies, Inc.
Bluebird Bio, Inc.
Lonza
Thermo Fisher Scientific, Inc

Recent Developments

In April 2024, Regeneron Pharmaceuticals collaborated with Mammoth Biosciences. This collaboration is done to use Mammoth’s platform with Regeneron to develop in vivo therapies for tissues.
In April 2024, Nvelop launched gene-editing cargo. Through this launch, Nvelop aimed to improve gene therapy delivery.
In April 2024, Profluent launched an AI model that can generate CRISPR proteins. Through this launch, the company claimed that the usage of AI can create a large number of CRISPR proteins that help manufacture bespoke cures.
In January 2024, Danaher Corporation collaborated with Innovative Genomics Institute (IGI). This collaboration aimed to develop gene editing therapies for the treatment of rare diseases and other diseases.
In April 2023, Synthego Corp launched Express Knockout Cell Pools. This launch aimed to use Express Knockout Cell Pools for several research applications ranging from disease modelling to loss-of-function screens along with drug discovery.

Segments Covered in the Report

By Technology

(CRISPR)/Cas9
ZFN
Meganuclease
TALENs/MegaTALs
Others

By Delivery Method

Ex-vivo
In-vivo

By Application

Genetic Engineering
- Cell Line Engineering
- Plant Genetic Engineering
- Animal Genetic Engineering
- Others
Clinical Applications
- Diagnostics
- Therapy Development

By Mode